Denali Therapeutics Inc (NASDAQ: DNLI) on Monday, plunged -6.77% from the previous trading day, before settling in for the closing price of $21.26. Within the past 52 weeks, DNLI’s price has moved between $14.56 and $33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 350.08%. The company achieved an average annual earnings per share of -162.04%. With a float of $124.65 million, this company’s outstanding shares have now reached $143.84 million.
Let’s determine the extent of company efficiency that accounts for 445 employees. In terms of profitability, gross margin is 102.06%, operating margin of 165.42%, and the pretax margin is 140.13%.
Denali Therapeutics Inc (DNLI) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Denali Therapeutics Inc is 13.39%, while institutional ownership is 88.50%. The most recent insider transaction that took place on Jan 02 ’25, was worth 64,403. In this transaction Director of this company sold 3,080 shares at a rate of $20.91, taking the stock ownership to the 107,976 shares. Before that another transaction happened on Jan 02 ’25, when Company’s Director proposed sale 6,160 for $20.38, making the entire transaction worth $125,541.
Denali Therapeutics Inc (DNLI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -162.04% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Denali Therapeutics Inc (DNLI) is currently performing well based on its current performance indicators. A quick ratio of 9.98 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.76, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -2.97 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Looking closely at Denali Therapeutics Inc (NASDAQ: DNLI), its last 5-days average volume was 0.86 million, which is a drop from its year-to-date volume of 0.99 million. As of the previous 9 days, the stock’s Stochastic %D was 34.32%. Additionally, its Average True Range was 1.07.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 0.66%, which indicates a significant decrease from 2.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.47% in the past 14 days, which was lower than the 54.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.74, while its 200-day Moving Average is $23.09. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $20.90. Second resistance stands at $21.97. The third major resistance level sits at $22.56. If the price goes on to break the first support level at $19.24, it is likely to go to the next support level at $18.65. Should the price break the second support level, the third support level stands at $17.58.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
Market capitalization of the company is 2.85 billion based on 143,922K outstanding shares. Right now, sales total 330,530 K and income totals -145,220 K. The company made 0 K in profit during its latest quarter, and -107,190 K in sales during its previous quarter.
